Skip to main content

Table 3 VDR, CYP27B1 and CYP24A1 and other breast cancer biomarkers expression in carcinomas in situ

From: Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions Vitamin D pathways unbalanced in breast lesions

   VDR CYP27B1 CYP24A1
   + (%) - (%) + (%) - (%) + (%) - (%)
ER + (%) 46 (35.1) 38 (29.0) 58 (42.3) 29 (21.2) 41 (32.8) 36 (28.8)
  - (%) 16 (12.2) 31 (23.7) 33 (24.1) 17 (12.4) 29 (23.2) 19 (15.2)
  p value 0.0227 ns ns
HER2 + (%) 9 (6.9) 14 (10.7) 18 (13.1) 7 (5.1) 9 (7.2) 12 (9.6)
  - (%) 53 (40.5) 55 (42.0) 73 (53.3) 39 (28.5) 61 (48.8) 43 (34.4)
  p value ns ns ns
PgR + (%) 35 (26.7) 30 (22.9) 49 (35.8) 18 (13.1) 38 (30.4) 22 (17.6)
  - (%) 27 (20.6) 39 (29.8) 42 (30.7) 28 (20.4) 32 (25.6) 33 (26.4)
  p value ns ns ns
CK5 + (%) 3 (2.3) 8 (6.1) 7 (5.1) 4 (2.9) 8 (6.4) 4 (3.2)
  - (%) 59 (45.0) 61 (46.6) 84 (61.3) 42 (30.7) 62 (49.6) 51 (40.8)
  p value ns ns ns
EGFR + (%) 1 (0.8) 5 (3.8) 2 (1.5) 5 (3.7) 5 (4.0) 3 (2.4)
  - (%) 61 (46.6) 64 (48.9) 89 (65.0) 41 (29.9) 65 (52.0) 52 (41.6)
  p value ns 0.0295 ns
P-cad + (%) 4 (3.1) 16 (12.2) 14 (10.2) 12 (8.8) 16 (12.8) 7 (5.6)
  - (%) 58 (44.3) 53 (40.5) 77 (56.2) 34 (24.8) 54 (43.2) 48 (38.4)
  p value 0.0078 ns ns
  1. ns: not significant.